Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1700761 | 1.00 | KIF11 (0.70) | KIF11DNMT1 | |
| S-Trityl-L-Cysteine SCHEMBL768202 | 0.82 | KIF11 (0.85) | KIF11DNMT1 | |
| S-Trityl-L-Cysteine SCHEMBL768203 | 0.82 | KIF11 (0.85) | KIF11DNMT1 | |
| S-Trityl-L-Cysteine SCHEMBL6891349 | 0.82 | KIF11 (0.85) | KIF11DNMT1 | |
| SCHEMBL14432746 | 0.82 | KIF11 (1.00) | KIF11DNMT1 | |
| Hydrochloric Acid SCHEMBL13736624 | 0.82 | KIF11 (0.71) | KIF11DNMT1 | |
| SCHEMBL14432747 | 0.82 | KIF11 (1.00) | KIF11DNMT1 | |
| SCHEMBL1700759 | 0.82 | KIF11 (1.00) | KIF11DNMT1 | |
| S-Trityl-L-Cysteine SCHEMBL655694 | 0.80 | KIF11 (0.82) | KIF11DNMT1 | |
| S-Trityl-L-Cysteine SCHEMBL11190178 | 0.80 | KIF11 (0.82) | KIF11DNMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2566334-B1 | CONTROLLED DRUG RELEASE FROM SOLID SUPPORTS | PROLYNX LLC (US) | 2018-04-18 | — | — | EP | disclosed |
| US-8946405-B2 | Controlled release from solid supports | PROLYNX LLC (US) | 2015-02-03 | — | — | US | disclosed |
| CN-103740648-A | Kinesin spindle protein (Eg5) monoclonal antibody and hybridoma cell strain secreting it | CHENGDU ZEN BIOSCIENCE CO LTD | 2014-04-23 | — | — | CN | disclosed |
| US-8703907-B2 | Controlled drug release from dendrimers | PROLYNX LLC (US) | 2014-04-22 | — | — | US | disclosed |
| US-20130123461-A1 | CONTROLLED DRUG RELEASE FROM DENDRIMERS | PROLYNX LLC (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130123487-A1 | CONTROLLED RELEASE FROM SOLID SUPPORTS | PROLYNX LLC (US) | 2013-05-16 | — | — | US | disclosed |
| EP-2571496-A1 | CONTROLLED DRUG RELEASE FROM DENDRIMERS | Prolynx Llc (US) | 2013-03-27 | — | — | EP | disclosed |
| EP-2566334-A1 | CONTROLLED DRUG RELEASE FROM SOLID SUPPORTS | Prolynx Llc (US) | 2013-03-13 | — | — | EP | disclosed |
| WO-2011140376-A1 | CONTROLLED DRUG RELEASE FROM DENDRIMERS | PROLYNX LLC (US) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011140392-A1 | CONTROLLED DRUG RELEASE FROM SOLID SUPPORTS | PROLYNX LLC (US) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123487-A1 | CONTROLLED RELEASE FROM SOLID SUPPORTS | SLC43A1, ABCB1, NAPA | KIF11 2609/4885DNMT1 793/4885 |
| US-20130123461-A1 | CONTROLLED DRUG RELEASE FROM DENDRIMERS | SLC43A1, SLC47A1, SLC47A2 | KIF11 1309/4885DNMT1 290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.